NVAX Share Price

Open 1.03 Change Price %
High 1.07 1 Day 0.00 0.00
Low 0.96 1 Week -0.01 -0.97
Close 1.02 1 Month 0.21 25.93
Volume 7455014 1 Year -4.48 -81.45
52 Week High 8.49
52 Week Low 0.73
NVAX Important Levels
Resistance 2 1.12
Resistance 1 1.08
Pivot 1.02
Support 1 0.96
Support 2 0.92
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
DCTH 0.02 -33.33%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
HMNY 3.81 55.51%
LOCM 0.09 50.00%
GSOL 17.88 49.00%
OPXAW 0.04 33.33%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BEBE 4.67 23.22%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
HAUP 0.07 -58.82%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 4
As on 23rd May 2017 NVAX Share Price closed @ 1.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.91 & Sell for SHORT-TERM with Stoploss of 1.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for May
1st Target up-side 1.13
2nd Target up-side 1.34
3rd Target up-side 1.55
1st Target down-side 0.51
2nd Target down-side 0.3
3rd Target down-side 0.09
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.